Using Citra-Lock 46,7%
Since the introduction of Citra-Lock (46,7%) to the renal departmant of St.Bard’s renal unit (Royal London Hospital) has proven record in managing MRSA.
The number of MRSA infections has fallen from 2,27/1000 patiens catheter days to 1,36/1000 patiens catheter days.
Citra-Lock intervention provides significant benefit to patiens, provides an extra 2-3 bed days to the hospital an provides savings of € 145.000,- .
Citra-Lock™ is based on higly concentrated trisodium citrate that prevents clotting and therefore helps maintaining high flow rates whilst greatly reducing the need for Urokinase/tPA and otheter replacements.
Trisodium citrate (TSC) lowers infection rates by reducing biofilm formation in hemodialysis catheters. The study of Bosma (2009) demonstrates an in vivo reduction of intraluminal catheter biofilm formation and bacterial colonizasion with the use of TSC 30% for HD catheter locking. By this mechanism, prevention of catheter-related infections by TSC can be largely explained.
Increase Safety & Simplified handling
Citra-Gen products are part of international recommended guidelines of today, defined by clinicians. Citra-Gen presents its products worldwide through a global network of dedicated distributors. Therefore, Citra-Gen is able to offer a high level of support to local customers.
Effective range of biocompatible catheters, prepared for state of the art blood flows.— Citra-XS™ Catheters
Citra-Lock™ is recommended in the European Renal Best Practice Guidelines (ERBP) and the American Society of Diagnostic and Interventional Nephrology (ASDIN).— Citra-Lock™